Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 Prostate cancerProstate cancer
展开 Epidemiological aspects of prostate cancerEpidemiological aspects of prostate cancer
展开 Diagnostic aspects of prostate cancerDiagnostic aspects of prostate cancer
折叠 Therapeutic aspects of prostate cancerTherapeutic aspects of prostate cancer
展开 Deferred treatmentDeferred treatment
展开 SurgerySurgery
展开 RadiotherapyRadiotherapy
展开 CryotherapyCryotherapy
展开 Hormonal therapyHormonal therapy
展开 ChemotherapyChemotherapy
展开 Castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancer (CRPC)
展开 Metastatic prostate cancerMetastatic prostate cancer
折叠 Other treatmentOther treatment
展开 Management of prostate cancer in older menManagement of prostate cancer in older men
展开 Options other than surgery and radiotherapy for the primary treatment of localised prostate cancerOptions other than surgery and radiotherapy for the primary treatment of localised prostate cancer
展开 Post-treatment quality of life in patients with localised prostate cancerPost-treatment quality of life in patients with localised prostate cancer
展开 Treatment of PSA-only recurrence after treatment with curative intentTreatment of PSA-only recurrence after treatment with curative intent
Post-treatment quality of life in patients with localised prostate cancer
Preferred Name Post-treatment quality of life in patients with localised prostate cancer
Definition Increased life expectancy in PCa makes post-treatment QoL a key issue. Health-related QoL (HRQoL) refers to the impact of disease and treatment on well-being and physical, emotional and social functioning, including daily functioning. HRQoL is rated by patients, and is important because physicians often underestimate the impact of disease and treatment on patients. PCa-specific HRQoL refers to the disease-specific outcome of PCa, including urinary, bowel and sexual functioning. General HRQoL refers to well-being, vitality, fatigue, pain, general health status, global QoL, and life satisfaction. HRQoL is measured using standardised questionnaires, which provide an objective assessment of general and disease-specific domains. Comparison of the most common contemporary therapies for localised PCa is necessary to inform patients about treatment options and address patient preferences for the various possible outcomes. There is still limited objective data about HRQoL in PCa treatment.
Synonyms & Abbreviations Post-treatment quality of life in patients with localised prostate cancer
ReferenceCode NA
ReferenceURL NA
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.